Table C26Body mass index 27 kg/m2

Total QALYsTotal costs (£)Inc. QALYInc. cost (£)ICER
Human insulin8.0719,440
Pioglitazone8.0719,964−0.000523dominated
Glargine8.0421,428−0.0251,988dominated
Biphasic analogue8.0722,9540.0023,514ED
Rosiglitazone7.9824,958−0.0865,518dominated
Exenatide8.1328,9750.0649,535£149,868

From: Appendix C, Health economic analysis of third-line therapy with insulins, glitazones or exenatide in Type 2 diabetes

Cover of Type 2 Diabetes
Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update).
NICE Clinical Guidelines, No. 66.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.